SecBot SecBot
PRESS-RELEASE ·Filed Sep 14, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 8/10
Horizonimmediate Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a major de-risking and revenue catalyst for Telix, establishing a new commercial product in a large unmet-need market. Traders should expect significant upside on the open; watch for initial sales ramp commentary and potential analyst upgrades. The Phase 3 brain metastases expansion study adds further pipeline optionality.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$11.78
T+0 close · Sep 14, 2026 · via day close
Latest settled
−4.16%
T+20 · $11.29 · next T+60 in 21d
Vs SPY
−6.42%
α at T+20
Latest observation
−17.75%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $11.78entry
  2. T+1 · 2mo ago +8.91%α +9.37% · $12.83
  3. T+5 · 8w ago −3.99%α −4.10% · $11.31
  4. T+20 · 5w ago −4.16%α −6.42% · $11.29
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer), for differentiating recurrent or progressive glioma from treatment-related change in adults and pediatric patients. This approval addresses a significant unmet need in a market with ~24,000 new U.S. glioma cases annually and reinforces Telix's leadership in theranostics, expanding its commercial precision diagnostics portfolio alongside Illuccix and Gozellix. The approval is a transformative catalyst for Telix, particularly as an early-stage biotech with a first-in-class commercial asset in a new indication, likely driving substantial stock appreciation.

Key Facts

  • FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients 1 month+
  • Pixclara is the first FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
  • Approximately 24,000 new glioma cases are diagnosed in the U.S. each year
  • FET-PET imaging is recommended in international clinical practice guidelines including NCCN Guidelines
  • Pixclara is also in a Phase 3 registrational study for potential indication expansion for brain metastases
  • Telix is a commercial-stage radiopharmaceutical company with a precision diagnostics portfolio including Illuccix and Gozellix

Financial Impact

First FDA-approved FET-PET imaging drug for glioma in a ~24,000 annual U.S. case market; transformative for Telix's commercial diagnostics business

revenuemarket sharepipeline valuation

Risk Factors

  • Competition from off-label use of non-FDA-approved FET-PET agents or alternative imaging modalities
  • Reimbursement and market access challenges for a new diagnostic agent
  • Potential for slower-than-expected physician adoption despite guideline recommendations

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3360898

Track record

27 reports on TLX

Performance horizon

9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Viewing Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026